Adverse Effects of Antiepileptic Drugs

ABSTRACT

Adverse effects of antiepileptic drugs (AEDs) are considered by patients to be at least as important as repetitive seizures in terms of quality of life. AED toxicity is frequent and contributes to a high proportion of treatment failures. Despite its high prevalence and clinical relevance, screening for adverse reactions to AEDs is not systematically included in everyday clinical practice; therefore it is very likely that it remains underestimated. Because there is little difference among AEDs in terms of efficacy, drug selection is often based on the adverse effects profile. AED toxicity is classified according to different parameters, such as severity, time of occurrence, organ system involvement, and mechanisms of action. Although most toxic reactions to drugs can be predicted from cumulative experience, prevention is not always possible, since multiple mechanisms and individual susceptibility to each drug participate in the final outcome. However, adverse effects can be reduced and appropriate action can be taken in time by means of a high degree of suspicion, knowledge of risk factors, and close follow-up. This article highlights factors to consider for detecting and managing AED adverse effects.

Adverse events - antiepileptic drugs

REFERENCES

• 1 Fisher R S, Vickrey B G, Gibson P et al.. The impact of epilepsy from the patient's perspective II: views about therapy and health care.  Epilepsy Res. 2000;  41 53-61
• 2 Baker G A, Jacoby A, Buck D, Stalgis C, Monnet D. Quality of life of people with epilepsy: a European study.  Epilepsia. 1997;  38 353-362
• 3 Gilliam F G, Fessler A J, Baker G, Vahle V, Carter J, Attarian H. Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial.  Neurology. 2004;  62 23-27
• 4 Perucca E, Meador K J. Adverse effects of antiepileptic drugs.  Acta Neurol Scand Suppl. 2005;  181 30-35
• 5 Rowan A J, Ramsay R E, Collins J F et al.. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine.  Neurology. 2005;  64 1868-1873
• 6 Deckers C LP, Hekster Y A, Keyser A, Van Lier H J, Meinardi H, Renier W O. Monotherapy vs polytherapy for epilepsy: a multicentre double-blind randomised study.  Epilepsia. 2001;  42 1387-1394
• 7 Meador K J. Cognitive and memory effects of the new antiepileptic drugs.  Epilepsy Res. 2006;  68 63-67
• 8 Gilliam F G, Veloso F, Bomhof M AM et al.. A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy.  Neurology. 2003;  60 196-202
• 9 Kanner A M, Wuu J, Faught E, Tatum IV W O, Fix A, French J A. the PADS Investigators . A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events.  Epilepsy Behav. 2003;  4 548-552
• 10 Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs.  Epilepsia. 2007;  48 1223-1244
• 11 Arif H, Buchsbaum R, Weintraub D et al.. Comparison and predictors of rash associated with 15 antiepileptic drugs.  Neurology. 2007;  68 1701-1709
• 12 Alvestad S, Lydersen S, Brodtkorb E. Rash from antiepileptic drugs: influence by gender, age, and learning disability.  Epilepsia. 2007;  48 1360-1365
• 13 Hirsch L J, Weintraub D B, Buchsbaum R et al.. Predictors of lamotrigine-associated rash.  Epilepsia. 2006;  47 318-322
• 14 Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics.  Neurology. 2005;  64 1134-1138
• 15 Pellock J M, Faught E, Leppik I E, Shinnar S, Zupanc M L. Felbamate: consensus of current clinical experience.  Epilepsy Res. 2006;  71 89-101
• 16 Ibáñez L, Vidal X, Ballarín E, Laporte J R. Population-based drug-induced agranulocytosis.  Arch Intern Med. 2005;  165 869-874
• 17 Levinson D F, Devinsky O. Psychiatric adverse events during vigabatrin therapy.  Neurology. 1999;  53 1503-1511
• 18 Mula M, Trimble M R, Lhatoo S D, Sander J W. Topiramate and psychiatric adverse events in patients with epilepsy.  Epilepsia. 2003;  44 659-663
• 19 Mula M, Trimble M R, Yuen A, Liu R S, Sander J W. Psychiatric adverse events during levetiracetam therapy.  Neurology. 2003;  61 704-706
• 20 Chaves J, Sander J W. Seizure aggravation in idiopathic generalized epilepsies.  Epilepsia. 2005;  46(suppl 9) 133-139
• 21 Thomas P, Valton L, Genton P. Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy.  Brain. 2006;  129 1281-1292
• 22 Genton P. When antiepileptic drugs aggravate epilepsy.  Brain Dev. 2000;  22 75-80
• 23 Perucca E, Gram L, Avanzini G, Dulac O. Antiepileptic drugs as a cause of worsening seizures.  Epilepsia. 1998;  39 5-17
• 24 Guerrini R, Dravet C, Genton P, Belmonte A, Kaminska A, Dulac O. Lamotrigine and seizure aggravation in severe myoclonic epilepsy.  Epilepsia. 1998;  39 508-512
• 25 Wakai S, Ito N, Sueoka H, Kawamoto Y, Hayasaka H, Chiba S. Severe myoclonic epilepsy in infancy and carbamazepine.  Eur J Pediatr. 1996;  155 724
• 26 Corda D, Gelisse P, Genton P, Dravet C, Baldy-Moulinier M. Incidence of drug-induced aggravation in benign epilepsy with centrotemporal spikes.  Epilepsia. 2001;  42 754-759
• 27 Cerminara C, Montanaro M L, Curatolo P, Seri S. Lamotrigine-induced seizure aggravation and negative myoclonus in idiopathic rolandic epilepsy.  Neurology. 2004;  63 373-375
• 28 Hirsch E, Genton P. Antiepileptic drug-induced pharmacodynamic aggravation of seizures: does valproate have a lower potential?.  CNS Drugs. 2003;  17 633-640
• 29 Pellock J M, Wilder B J, Deaton R, Sommerville K W. Acute pancreatitis coincident with valproate use: a critical review.  Epilepsia. 2002;  43 1421-1424
• 30 Fraunfelder F W, Fraunfelder F T, Keates E U. Topiramate-associated acute, bilateral, secondary angle-closure glaucoma.  Ophthalmology. 2004;  111 109-111
• 31 Drory V E, Korczyn A D. Hypersensitivity vasculitis and systemic lupus erythematosus induced by anticonvulsants.  Clin Neuropharmacol. 1993;  16 19-29
• 32 Biton V, Mirza W, Montouris G, Vuong A, Hammer A E, Barrett P S. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy.  Neurology. 2001;  56 172-177
• 33 Ben-Menachem E, Axelsen M, Johanson E H, Stagge A, Smith U L. Predictors of weight loss in adults with topiramate-treated epilepsy.  Obes Res. 2003;  11 556-562
• 34 Reife R, Pledger G, Wu S C. Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults.  Epilepsia. 2000;  41(suppl 1) S66-S71
• 35 Sato Y, Kondo I, Ishida S et al.. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy.  Neurology. 2001;  57 445-449
• 36 Ensrud K E, Walczak T S, Blackwell T, Ensrud E R, Bowman P J, Stone K L. Antiepileptic drug use increases rates of bone loss in older women: a prospective study.  Neurology. 2004;  62 2051-2057
• 37 Petty S J, Paton L M, O'Brien T J et al.. Effect of antiepileptic medication on bone mineral measures.  Neurology. 2005;  65 1358-1365
• 38 Andress D L, Ozuna J, Tirschwell D et al.. Antiepileptic drug-induced bone loss in young male patients who have seizures.  Arch Neurol. 2002;  59 781-786
• 39 Chen S S, Shen M R, Chen T J, Lai S L. Effects of antiepileptic drugs on sperm motility of normal controls and epileptic patients with long-term therapy.  Epilepsia. 1992;  33 149-153
• 40 Isojärvi J IT, Löfgren E, Juntunen K ST et al.. Effect of epilepsy and antiepileptic drugs on male reproductive health.  Neurology. 2004;  62 247-253
• 41 Herzog A G, Drislane F W, Schomer D L et al.. Differential effects of antiepileptic drugs on sexual function and hormones in men with epilepsy.  Neurology. 2005;  65 1016-1020
• 42 Gil-Nagel A, Lopez-Munoz F, Serratosa J M, Moncada I, Garcia-Garcia P, Alamo C. Effect of lamotrigine on sexual function in patients with epilepsy.  Seizure. 2006;  15 142-149
• 43 Duncan S. Polycystic ovarian syndrome in women with epilepsy: a review.  Epilepsia. 2001;  42 60-65
• 44 Isojärvi J IT, Taubøll E, Pakarinen A J et al.. Altered ovarian function and cardiovascular risk factors in valproate treated women.  Am J Med. 2001;  111 290-296
• 45 Mikkonen K, Vainionpää L K, Pakarinen A J et al.. Long-term female reproductive endocrine health in young women with epilepsy during puberty.  Neurology. 2004;  62 445-450
• 46 Vainionpää L K, Rättyä J, Knip M et al.. Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy.  Ann Neurol. 1999;  45 444-450
• 47 Isojärvi J I, Rättyä J, Myllylä V V et al.. Valproate, lamotrigine and insulin-mediated risks in women with epilepsy.  Ann Neurol. 1998;  43 446-451
• 48 McDonagh J, Stephen L J, Dolan F M et al.. Peripheral retinal dysfunction in patients taking vigabatrin.  Neurology. 2003;  61 1690-1694
• 49 Malmgren K, Ben-Menachem E, Frisén L. Vigabatrin visual toxicity: evolution and dose dependence.  Epilepsia. 2001;  42 609-615
• 50 De Marcos F A, Ghizoni E, Kobayashi E, Li L M, Cendes F. Cerebellar volume and long-term use of phenytoin.  Seizure. 2003;  12 312-315
• 51 Holmes L B, Harvey E A, Coull B A et al.. The teratogenicity of anticonvulsant drugs.  N Engl J Med. 2001;  344 1132-1138
• 52 Pennell P B. The importance of monotherapy in pregnancy.  Neurology. 2003;  60 S31-S38
• 53 Vajda F J, Eadie M J. Maternal valproate dosage and fetal malformations.  Acta Neurol Scand. 2005;  112 137-143
• 54 Meador K J, Baker G A, Finnell R H et al.. In utero antiepileptic drug exposure: fetal death and malformations.  Neurology. 2006;  67 407-412
• 55 Morrow J, Russell A, Guthrie E et al.. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register.  J Neurol Neurosurg Psychiatry. 2006;  77 193-198
• 56 Holmes L B, Wyszynski D F, Lieberman E. The AED (antiepileptic drug) pregnancy registry: a 6-year experience.  Arch Neurol. 2004;  61 673-678
• 57 Tomson T, Battino D, Bonizzoni E et al.. EURAP: an international registry of antiepileptic drugs and pregnancy.  Epilepsia. 2004;  45 1463-1464
• 58 Artama M, Auvinen A, Raudaskoski T, Isojärvi I, Isojärvi J. Antiepileptic drug use of women with epilepsy and congenital malformations in offspring.  Neurology. 2005;  64 1874-1878
• 59 Cunnington M, Tennis P. International Lamotrigine Pregnancy Registry Scientific Advisory Committee . Lamotrigine and the risk of malformations in pregnancy.  Neurology. 2005;  64 955-960
• 60 Adab N, Kini U, Vinten J et al.. The longer term outcome of children born to mothers with epilepsy.  J Neurol Neurosurg Psychiatry. 2004;  75 1575-1583
• 61 Eriksson K, Viinikainen K, Monkkonen A et al.. Children exposed to valproate in utero: population-based evaluation of risks and confounding factors for long-term neurocognitive development.  Epilepsy Res. 2005;  65 189-200
• 62 Gaily E, Kantola-Sorsa E, Hiilesmaa V et al.. Normal intelligence in children with prenatal exposure to carbamazepine.  Neurology. 2004;  62 28-32
• 63 Vinten J, Adab N, Kini U, Gorry J, Gregg J, Baker G A. Liverpool and Manchester Neurodevelopment Study Group . Neuropsychological effects of exposure to anticonvulsant medication in utero.  Neurology. 2005;  64 949-954
• 64 Singh G, Driever P H, Sander J W. Cancer risk in people with epilepsy: the role of antiepileptic drugs.  Brain. 2005;  128 7-17
• 65 Lamminpää A, Pukkala E, Teppo L, Neuvonen P J. Cancer incidence among patients using antiepileptic drugs: a long-term follow-up of 28,000 patients.  Eur J Clin Pharmacol. 2002;  58 137-141
• 66 Adelöw C, Ahlbom A, Feychting M, Jonson F, Schwartzbaum J, Tomson T. Epilepsy as a risk factor for cancer.  J Neurol Neurosurg Psychiatry. 2006;  77 784-786
• 67 Olsen J H, Schulgen G, Boice J D et al.. Antiepileptic treatment and risk for hepatobiliary cancer and malignant lymphoma.  Cancer Res. 1995;  55 294-297
• 68 Patsalos P N, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs.  Lancet Neurol. 2003;  2 347-356
• 69 French J A, Barry E G. Antiepileptic drug interactions.  Epilepsia. 2000;  41(suppl 8) S30-S36
• 70 Kanner A M, Frey M. Adding valproate to lamotrigine: a study of their pharmacokinetic interaction.  Neurology. 2000;  55 588-591